Aptevo Therapeutics
Most recent annual filing: 2026-03-26
- Mipletamig Ph2 readoutyear-end 2026Mipletamig Ph2 readout, year-end 2026, major
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (8 active programs)
ALG.APV-527
APVO603
- Undisclosed indication
APVO442
APVO711
- Undisclosed indication
APVO455
- Undisclosed indication
APVO451
APVO452
Technology platforms
ADAPTIR
ADAPTIR protein technology platform for rational design of monospecific and bispecific immunotherapeutic proteins targeting cancer; generates molecules that bind one or more targets with structural and functional advantages over monoclonal antibodies; used to develop clinical and preclinical oncology candidates
Targets: CD3, Nectin-4, PD-L1
ADAPTIR-FLEX
Proprietary flexible multispecific immunotherapy platform enabling adjustable construct design and addition of different therapeutic components; supports development of bispecific and trispecific candidates for solid tumors and hematologic malignancies, including Nectin-4 x PD-L1 backbone applications.
Targets: CD3, Nectin-4, PD-L1
Biotech Distilled coverage (4)
- 2026-09-03 UPDATE: Aptevo Therapeutics (APVO) - Good Data, Wrong Week 🔒 Paid
- 2026-08-15 UPDATE: Aptevo Therapeutics (APVO) - They Just Locked Their Own Piggy Bank 🔒 Paid
- 2026-08-13 UPDATE: Aptevo Therapeutics (APVO) - The Warrant Treadmill Turns Again 🔒 Paid
- 2026-06-16 Aptevo Therapeutics (APVO) - Scientific Deep Dive for Mipletamig, ALG.APV-527, and the ADAPTIR Pipeline
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.